Section Arrow
DBVT.NASDAQ
- DBV Technologies S.A
Quotes are at least 15-min delayed:2025/11/16 10:58 EST
Regular Hours
Last
 13.24
+0.18 (+1.38%)
Day High 
13.66 
Prev. Close
13.06 
1-M High
18 
Volume 
18.18K 
Bid
6.78
Ask
17.62
Day Low
12.98 
Open
12.98 
1-M Low
12.56 
Market Cap 
469.49M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 13.91 
20-SMA 14.73 
50-SMA 12.79 
52-W High 18 
52-W Low 2.2045 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.20/-4.70
Enterprise Value
475.78M
Balance Sheet
Book Value Per Share
1.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 10:58 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.